UB 421

Drug Profile

UB 421

Alternative Names: dB4; dB4C7 mAb; mAb B4; UB421

Latest Information Update: 28 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator United Biomedical
  • Developer United Biomedical; United BioPharma
  • Class Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action HIV fusion inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 30 May 2018 United BioPharma plans a phase IIb/III trial for HIV-1 infection (Adjunctive therapy, Second-line therapy or greater) in USA (IV, Infusion) in September 2018 (NCT03164447)
  • 28 Nov 2017 United Biopharma files IND applications with regulatory authorities in China and Thailand for a phase III trial in HIV-1 infections prior to November 2017
  • 17 Nov 2017 The Taiwan's Ministry of Health approves an IND application for a phase III trial for HIV-1 infections prior to November 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top